Osteonecrosis of the jaw in FN Brno - years 2004 - 2012
analysis.

a 2013

Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis.

PEŘINA, Vojtěch, Zdeněk DANĚK a Oliver BULIK

Základní údaje

Originální název

Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis.

Název česky

Osteonekrózy čelisti ve FN Brno - analýza let 2004 - 2012.

Autoři

PEŘINA, Vojtěch, Zdeněk DANĚK a Oliver BULIK

Vydání

Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice, 2013

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

ISBN

978-80-87562-11-6

Změněno: 13. 7. 2014 13:35, doc. MUDr. et MUDr. Vojtěch Peřina, Ph.D.

Anotace

V originále

Bisphosphonates (BP) are widely used in the management of metastatic bone disease including multiple myeloma (MM) and in the treatment of osteoporosis or Paget's disease. The association between BP treatment and osteonecrosis of the jaw is known since 2003. During years 2004 - 2012 we have diagnosed 93 patients with BP-associated osteonecrosis of the jaw (BPOJ). The most common main diagnoses were MM and solid cancers bone metastases. While number of patient with MM and BPOJ stays relatively stable (aprox. 5 patients per year) number of patients with bone metastases rise each year (from 0 in the year 2004 to 17 in 2012). One reason is undoubtedly wider use of BP for bone metastases treatment nowadays. But we noticed worse patient's education and preventive measures among patients with solid cancers. This is probably due to higher centralization of hematooncological care and closer cooperation between hematooncologists and OMF surgeons in our hospital. The general oncological and supportive care is more fragmented and the risk of BPOJ is not well known. In the future better patient's education and wider interdisciplinary cooperation will be necessary. Early diagnosis (even before clinical manifestation of BPOJ), would be advantageous. But then most suitable modality is still open question.

Návaznosti

GAP102/11/0318, projekt VaV

Název: Analýza metabolizmu a lokalizace změn kostní tkáně čelisti pomocí MR zobrazovacích technik

Investor: Grantová agentura ČR, Analýza metabolizmu a lokalizace změn kostní tkáně čelisti pomocí MR zobrazovacích technik

Citovat

PEŘINA, Vojtěch, Zdeněk DANĚK a Oliver BULIK. Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis. In Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice. 2013. ISBN 978-80-87562-11-6.

@proceedings{1131035,
   author = {Peřina, Vojtěch and Daněk, Zdeněk and Bulik, Oliver},
   booktitle = {Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice},
   isbn = {978-80-87562-11-6},
   title = {Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis.},
   year = {2013}
}

TY  - CONF
ID  - 1131035
AU  - Peřina, Vojtěch - Daněk, Zdeněk - Bulik, Oliver
PY  - 2013
TI  - Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis.
SN  - 9788087562116
N2  - Bisphosphonates (BP) are widely used in the management of metastatic bone disease including multiple myeloma (MM) and in the treatment of osteoporosis or Paget's disease. The association between BP treatment and osteonecrosis of the jaw is known since 2003. During years 2004 - 2012 we have diagnosed 93 patients with BP-associated osteonecrosis of the jaw (BPOJ). The most common main diagnoses were MM and solid cancers bone metastases. While number of patient with MM and BPOJ stays relatively stable (aprox. 5 patients per year) number of patients with bone metastases rise each year (from 0 in the year 2004 to 17 in 2012). One reason is undoubtedly wider use of BP for bone metastases treatment nowadays. But we noticed worse patient's education and preventive measures among patients with solid cancers. This is probably due to higher centralization of hematooncological care and closer cooperation between hematooncologists and OMF surgeons in our hospital. The general oncological and supportive care is more fragmented and the risk of BPOJ is not well known. In the future better patient's education and wider interdisciplinary cooperation will be necessary. Early diagnosis (even before clinical manifestation of BPOJ), would be advantageous. But then most suitable modality is still open question.
ER  -

PEŘINA, Vojtěch, Zdeněk DANĚK a Oliver BULIK. Osteonecrosis of the jaw in FN Brno - years 2004 - 2012 analysis. In \textit{Sborník abstrakt, 10. česko-slovensko-polské trilaterální sympozium orální a maxilofaciální chirurgie a 2. národní kongres Společnosti maxilofaciální chirurgie, 07.-09.11.2013, Velké Karlovice}. 2013. ISBN~978-80-87562-11-6.

Podrobný výpis o publikaci